Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001214659-24-016381 0001232621 XXXXXXXX LIVE 1 Common Shares, no par value 02/28/2025 false 0001600620 05156V102 Aurinia Pharmaceuticals Inc. #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 10029500.00 0.00 10029500.00 10029500.00 N 7.3 OO Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III") and Kevin Tang. The percentages used herein are based on 137,339,016 Common Shares outstanding as of February 25, 2025, as set forth in the Issuer's Annual Report filed on Form 10-K that was filed with the Securities and Exchange Commission on February 27, 2025. 0001178579 N KEVIN TANG WC N X1 0.00 10029500.00 0.00 10029500.00 10029500.00 N 7.3 IN Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III and TCM. 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 5140591.00 0.00 5140591.00 5140591.00 N 3.7 PN TCP shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 4388909.00 0.00 4388909.00 4388909.00 N 3.2 PN TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS III, INC WC N NV 0.00 500000.00 0.00 500000.00 500000.00 N 0.4 CO TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang. Y TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 0.00 0.00 0.00 0.00 N 0 CO Common Shares, no par value Aurinia Pharmaceuticals Inc. #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 This Schedule 13D/A (this "Statement") amends the Schedule 13D (the "Original Schedule 13D") filed on September 12, 2024. Items 2, 3, 5 and 7 of the Statement are hereby amended and supplemented to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D. The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following: This Statement is filed by TCM, a Delaware limited liability company that is the general partner of TCP and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; TCP III, a Nevada corporation that is indirectly wholly owned by TCP; and Tang Capital Partners IV, Inc., a Nevada corporation that is indirectly wholly owned by TCP ("TCP IV" and, collectively with TCM, Kevin Tang, TCP, TCPI, and TCP III, the "Reporting Persons"). The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 5955 Edmond Street, Las Vegas, NV 89118. Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. See Item 2(a) above. Item 3 of the Original Schedule 13D is hereby amended to add the following: Since September 12, 2024 the Reporting persons have expended an aggregate of approximately $23.5 million to purchase 2,800,000 of the Issuer's Common Shares through the open market. The Common Shares were acquired in the ordinary course of business. The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 10,029,500 of the Issuer's Common Shares, representing 7.3% of the outstanding shares. See item 5(a) above. Schedule A attached hereto as Exhibit 2 describes all transactions in the Issuer's Common Shares that were effected during the past 60 days by the Reporting Persons. No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Shares beneficially owned by the Reporting Persons. Not applicable Exhibit 1: Joint Filing Agreement by and among the Reporting Persons (as amended). Exhibit 2: Schedule A: Transactions during the past 60 days. TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang Manager 03/04/2025 KEVIN TANG /s/ Kevin Tang Self 03/04/2025 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 03/04/2025 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 03/04/2025 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang Chief Executive Officer 03/04/2025 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang Chief Executive Officer 03/04/2025